Anti-Human DR3/TNFRSF25

Quality Tested by Leinco Western Blotting: To detect Human DR3 this polyclonal antibody can be used at a concentration of 0.1-0.2 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as PN:G505 and a chromogenic substrate such as PN:T343. The detection limit for Human DR3 is 2 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used.

Death Receptor 3

Next Day Ambient

Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD1-5. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L. DR3 is highly expressed in the tissues enriched in lymphocytes including PBL, thymus and spleen. Like TNFR1, DR3 induces apoptosis and NF-κB activation.

Death Receptor 3

AB_2829931

< 0.1 EU/µg as determined by the LAL method

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.